Yale University
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Yale University sits in the top decile of US sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count).
Yale University: 1,492 sponsored US clinical trials, 254 recruiting.
Yale University sponsors 1,492 registered US clinical trials on ClinicalTrials.gov, 254 of them currently recruiting, and 1,005 completed. 99 of these trials are in Phase 3-4 (later-stage) and 579 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Opioid Use Disorder, with 19 trials.
Top-decile sponsor footprint
Yale University ranks in the top decile of sponsors by registered trial count (#13 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,005 of 1,138 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,492 total, page 9 of 30
Influence of Stress on Encoding and Prediction
NCT05920161
Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis
NCT05664763
Single-Session Web-Based Training in Self-Compassion
NCT05715034
Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases
NCT05408871
Dissemination and Implementation of Improving Pediatric Obesity Practice Using Prompts
NCT05627011
Nicotine Flux, a Potentially Powerful Tool for Regulating Nicotine Delivery From Electronic Cigarettes
NCT05706701
Cognitive Behavioral Therapy for Adolescents With Bulimia Nervosa and Higher Weight (Online Treatment Study)
NCT05770947
Cognitive Training in Parkinson's Disease
NCT05495997
Blood Pressure Monitoring in Hypertensive Populations: Device Testing, Feasibility, Acceptability
NCT05601414
A Digital Game Targeting Suicide Prevention in Adolescents Who Report Substance Misuse
NCT05517382
Safety and Effects on Responses to Stress and Pain of Natural Medical Marijuana Products
NCT04226690
Effects of E-cigarette Flavors on Youth TCORS 2.0
NCT03634839
Varenicline for Treatment of E-cigarette Dependence
NCT05541497
Developing e-Covery, an App-based Intervention to Support Individuals With Co-occurring Problem Alcohol and Opioid Use
NCT05325788
WithDRawal Impact Of Postoperative Beta-Blocker
NCT05414331
QBSafe: a Randomized Trial of a Novel Intervention to Improve Care for People Living With Type 2 Diabetes.
NCT05553912
Impact of Flavors on Nicotine Perception and Self-Administration Via E-cigarettes
NCT04038515
Defining Exercise Hemodynamics and Function After Transcatheter Aortic Valve Replacement (DEFINE-TAVR) Study.
NCT05567809
A Multi-level Intervention to Increase Access and Use of the Patient Portal
NCT05180721
Electronic Health Record Strategies to Promote Diverse Participation in Research
NCT05348603
Topical Antibacterial Agents for Prevention of COVID-19
NCT05449392
Standardized Field Test for Marijuana Impairment II
NCT05115513
Parametric Cardiac 18F-flutemetamol PET Imaging in ATTR Cardiomyopathy
NCT05374564
Water Content in E-Liquids
NCT05257109
Patient Navigator Intervention for Diabetic Retinopathy
NCT05188703
Computer Based Treatment for Cognitive Behavioral Therapy and Cooperative Pain Education and Self-Management
NCT05204576
Feasibility and Preliminary Efficacy of an Opioid Stewardship Program in Hospitalized Patients With Chronic Pain
NCT05370326
Postpartum Video Education
NCT05159726
Reducing Eco-anxiety Using Selfies
NCT05372705
Sex Differences in Neural Response to Cannabidiol
NCT04777643
Myoelectric Activity Following Colorectal Surgery and Return of Bowel Function
NCT05298774
Implementing and Evaluating a Social-Emotional Learning Program for Refugee Children During the COVID-19 Pandemic
NCT04931888
Effects of Menthol in E-cigarettes on Smoking Behaviors
NCT04521647
Novel Real-world Methods in Social Drinkers and AUD
NCT05155176
Randomized Study Of Novel Enuresis Alarm vs Standard Bedwetting Alarm
NCT05214131
Patient Self Measurement of Post-Void Residual Bladder Volume (PVR) Using Ultrasound
NCT05295823
Novel in Vivo Synaptic Imaging in Experienced Meditators
NCT05418608
Mindfulness Based Therapy for Insomnia in Black Women
NCT04951466
Characterizing Subjective and Physiological Responses to Stress and Pain and Cognitive Learning and Executive Function
NCT04419831
The Autism Biomarkers Consortium for Clinical Trials: Confirmation Study
NCT05294705
Reducing Suicide Risk in Adolescents and Young Adults Via a Psychobehavioral Intervention to Regularize Daily Rhythms
NCT05317481
Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis
NCT04173169
Community Partnership for Healthy Sleep: Sleep Well, Bee Well Part 2
NCT05130229
Reducing Transphobia Among Adolescents Through a Brief Video Intervention
NCT04969003
Effect of Endotoxin on Alcohol Consumption
NCT04527185
A PPG Sensor-Based Feedback Intervention for Heavy Drinking Young Adults
NCT05090995
Nicotine Differences in Smokers
NCT05159934
Compassion Training and Mindfulness Training for Social Well-Being and Mental Health
NCT05227794
A Pilot Study of Evidence-based Guided Self-help for the Treatment of Binge Eating
NCT05143866
Ocrelizumab for Preventing Clinical Multiple Sclerosis in Individuals With Radiologically Isolated Disease.
NCT04877457
What is open in the Yale University pipeline
254 recruiting of 1,492 indexed (17% open); 1,005 completed (67%).
Phase mix: 99 late (III/IV) vs 579 early (I/II) (early-phase heavy).
Top condition: Opioid Use Disorder (19 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Yale University: open-pipeline peers nationwide
Peers matched on 1,492 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Yale University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,492 trials (± recruiting share)
- Washington University School of Medicine · 1,502 trials · 14% recruiting
- Johns Hopkins University · 1,448 trials · 17% recruiting
- University of Pennsylvania · 1,423 trials · 14% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
Sponsors near 17% open enrollment (± trial volume)
- NYU Langone Health · 17% recruiting · 1,164 trials
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
Related
What to do with this Yale University page
1,492 registered trials is a research-attention snapshot, not an endorsement of Yale University or any single study.
- 254 of Yale University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Opioid Use Disorder is the condition Yale University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Opioid Use Disorder trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Yale University pipeline card: 1,492 registered trials from official public datasets.Report a data error.